Pierre Laumaille

Pierre Laumaille


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2019 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PLPierre Laumaille
Pierre Laumaille
Alexandra Dassonville-KlimptAlexandra Dassonville-Klimpt
Alexandra Dassonville-Klimpt
FPFrançois Peltier
François Peltier
CMCatherine Mullié
Catherine Mullié
CAClaire Andréjak
Claire Andréjak
Pascal SonnetPascal Sonnet
Pascal Sonnet
The lack of antibiotics with a novel mode of action associated with the spread of drug resistant bacteria make the fight against infectious diseases particularly challenging. A quinoline core is found in several anti-infectious drugs, such as mefloquine and bedaquiline. Two main objectives were set in this work. Firstly, we evaluated the anti-mycobacterial properties of the previous quinolines 3, which have been identified as good candidates against ESKAPEE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. and Escherichia coli) bacteria. Secondly, a new series 4 was designed and assessed against the same bacteria strains, taking the pair of enantiomers 3m/3n as the lead. More than twenty compounds 4 were prepared through a five-step asymmetric synthesis with good enantiomeric excesses (>90%). Interestingly, all compounds of series 3 were efficient on M. avium with MIC = 2–16 µg/mL, while series 4 was less active. Both series 3 and 4 were generally more active than mefloquine against the ESKAPEE bacteria. The quinolines 4 were either active against Gram-positive bacteria (MIC ≤ 4 µg/mL for 4c–4h and 4k/4l) or E. coli (MIC = 32–64 µg/mL for 4q–4v) according to the global lipophilicity of these compounds.

30 October 2019
Verified
Conference Paper
Open access
PLPierre Laumaille
Pierre Laumaille
Alexandra Dassonville-KlimptAlexandra Dassonville-Klimpt
Alexandra Dassonville-Klimpt
SNSophie Da Nascimento
Sophie Da Nascimento
CMCatherine Mullié
Catherine Mullié
FPFrançois Peltier
François Peltier
Pascal SonnetPascal Sonnet
Pascal Sonnet
Tuberculosis and nosocomial infections are among the most frequent causes of death in the world. Mycobacteria such as Mycobacterium tuberculosis and ESKAPE bacteria are pathogens particularly implicated in these infectious diseases1. The lack of antibiotics with novel mode of action associated with the spread of drug resistant bacteria make the fight against these infections particularly challenging. Using antimicrobial peptides (AMPs) to restore or to broaden antibacterial activity of antibiotics is an interesting strategy to fight resistant strains. For example, the conjugation between chloramphenicol and ubiquicidine29-41 gives a conjugate with increased activity against Escherichia coli and reduced toxicity against neutrophils compared to chloramphenicol alone 2. During previous work on the development of new anti-infective drugs, we identified a series of quinolines active against Gram-positive bacteria such as Staphylococcus aureus and Enterococcus faecalis. Concerning Gram-negative bacteria, some of them were active on E.coli but not against Pseudomonas aeruginosa3,4. In order to broaden the antibacterial spectrum of this heterocycle core, we synthesized quinoline-based conjugates with short AMP sequences5. Their antibacterial activities against a panel of bacteria and mycobacteria will be discussed. Membranotropic properties study through tensiometry measures on bacterial mimetic membrane models was carried out to elucidate their mechanism of action. References: (a) WHO, Global tuberculosis report 2017; (b) Khan, H. A., Baig, F. K. & Mehboob. Nosocomial infections: Epidemiology, prevention, control and surveillance, Asian Pac. J. Trop. Biomed. 2017, 7, 478–482. (a) Arnusch et al. Enhanced Membrane Pore Formation through High-Affinity Targeted Antimicrobial Peptides. PLoS ONE 2012 7:e39768; (b) Chen et al. Bacteria-Targeting Conjugates Based on Antimicrobial Peptide for Bacteria Diagnosis and Therapy. Mol. Pharm. 2015, 12, 2505. Jonet, A.; Dassonville-Klimpt, A.; Sonnet, P.; Mullié, C. Side chain length is more important than stereochemistry in the antibacterial activity of enantiomerically pure 4-aminoalcohol quinoline derivatives. J. Antibiot. (Tokyo) 2013, 66, 683–686. Laumaillé, Dassonville-Klimpt, Peltier, Mullié, Andréjak, Da-Nascimento, Castelain, Sonnet, Synthesis and study of new quinolineaminoethanols as anti-bacterial drugs, Pharmaceuticals 2019, 12(2), 91. Strøm, M. B. et al. The Pharmacophore of Short Cationic Antibacterial Peptides, 2003, 46, 3–6.

31 October 2018
Verified
Conference Paper
Open access
PLPierre Laumaille
Pierre Laumaille
Alexandra Dassonville-KlimptAlexandra Dassonville-Klimpt
Alexandra Dassonville-Klimpt
Pascal SonnetPascal Sonnet
Pascal Sonnet
Tuberculosis is regarded as one of the deadliest diseases in the world. In 2017, 10 million people were affected by tuberculosis and 1.7 million died because of it1. Tuberculosis is a bacterial infection caused by some bacteria from the genus Mycobacterium, such as Mycobacterium tuberculosis. Some bacterial strains are multi-resistant or extensively-resistant against classical antibiotics. Consequently, there is a necessity to set up new strategies to prevent the spread of antibiotic resistant mycobacteria. Only two antitubercular compounds have been commercialized during the last 40 years: bedaquiline in 20122 and delamanid in 2014. That emphasizes the lack of therapeutic options available to cure tuberculosis. Quinoline core is present in some antitubercular compounds. Indeed, bedaquiline is a diarylquinoline, which acts by inhibiting selectively the mycobacterial ATP synthase, an enzyme required for the energetic metabolism of the cell. The stereochemistry is particularly important in this selectivity as the (1R, 2S) enantiomer is 630 times more active than the (1S, 2R) enantiomer. Mefloquine is a quinoline used as antimalarial compound but this molecule shows also antimycobacterial properties. Indeed, mefloquine can inhibit ATP synthase of Streptococcus pneumoniae3. The objectives of this work are designing, synthesizing, and evaluating new antitubercular compounds as quinoline derivatives (AQM). These molecules are expected to inhibit mycobacterial ATP synthase in order to fight latent forms of mycobacteria. The previous works of the research team4 have allowed to identify a lead compound which shows an MIC of 2 µM against M. tuberculosis MtbH37Rv strain. A pharmacomodulation of this lead compound will be shown here. Twenty two molecules have been synthesized through an asymmetric synthetic route in 5 steps with an average yield from 14 to 47 %. These molecules have been tested in vitro, against M. avium and M. xenopi and have shown interesting biological activity with a MIC between 18 µM and more than 72 µM. WHO, Global tuberculosis report 2017. Haagsma AC, Abdillahi-Ibrahim R, et al. Antimicrob Agents Chemother. 2009, 53, 1290-1292. Martin-Galiano AJ, Gorgojo B, Kunin CM, de la Campa AG. Antimicrob Agents Chemother. 2002, 46, 1680-1697. Jonet, A. Dassonville-Klimpt, P. Sonnet, C. Mullié. J. of Antibiotics, 2013, 66, 683-686.